Italy Deployed Eyenuk's EyeArt AI Eye Screening System for First National Retinal and Diabetic Maculopathy Prevention and Diagnosis Campaign

LOS ANGELES--(BUSINESS WIRE)--Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced today that the EyeArt AI Eye Screening System was deployed successfully for Italy's first national prevention and diagnosis campaign for retinal and diabetic maculopathy. A total of 2,200 patients were screened at 30 centers across Italy, with more than half chosen for EyeArt AI Eye Screening. The Month of Prevention of Diabetic Retinopathy and Maculopathy was sponsored by the Italian Ministry of Health, the city of Milan and the Italian Ophthalmology Society in collaboration with the Ambrosian Ophthalmic Center (CAMO), San Raffaele Hospital and Eyenuk. In Italy, an estimated 3.2 million patients have diabetes. As many as 25% are estimated to be affected by diabetic retinopathy (DR),1 the main cause of vision impairment and blindness among working-age adults.